Takeda Pharmaceutical Company Limited (TAK)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Takeda Pharmaceutical Company Limited (TAK) is down 0.8% since the beginning of the year. At $15 per share, TAK is trading 18.1% below its 52-week high of $19. Investors who bought $1,000 worth of TAK shares 5 years ago would now be looking at an investment worth $1,105.

Takeda Pharmaceutical Company Limited (TAK) has returned -0.77% so far this year and 7.10% over the past 12 months. Over the last ten years, TAK has returned 0.64% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Oct 27, 2008, TAK's average daily return is +0.02%, while the average monthly return is +0.34%. At this rate, an investment would double in approximately 17.0 years.

Historically, 53% of months were positive and 47% were negative. The best month was Jan 2015 with a return of +20.9%, while the worst month was May 2013 at -18.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.

On a daily basis, TAK closed higher 51% of trading days. The best single day was Mar 10, 2009 with a return of +9.5%, while the worst single day was Mar 12, 2020 at -12.0%.

Takeda Pharmaceutical Company Limited has an annualized alpha of -1.93%, beta of 0.45, and R2 of 0.14 versus S&P 500 Index. Calculated based on daily prices since October 27, 2008.

• This stock participated in 51.46% of S&P 500 Index downside but only 27.56% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.45 may look defensive, but with R2 of 0.14 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.14 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TAK ranks 50 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

Takeda Pharmaceutical Company Limited provided a 2.08% dividend yield over the last twelve months, with an annual payout of $0.32 per share.

The table displays the monthly dividend distributions for Takeda Pharmaceutical Company Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Takeda Pharmaceutical Company Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Takeda Pharmaceutical Company Limited was 54.25%, occurring on Mar 18, 2020. The portfolio has not yet recovered.

The current Takeda Pharmaceutical Company Limited drawdown is 31.93%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Takeda Pharmaceutical Company Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Takeda Pharmaceutical Company Limited is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.